FDA Panel Says Obesity Drugs Need Tougher Clinical Trials

Law360, New York (March 29, 2012, 9:58 PM EDT) -- A U.S. Food and Drug Administration advisory committee reportedly recommended toughening its clinical trial requirements for obesity drugs on Thursday, requiring companies to test specifically for cardiovascular risks before receiving approval.

At the end of a two-day meeting of the Endocrinologic and Metabolic Drugs Advisory Committee focused on the assessment of heart risks in the approval process of weight-loss drugs, the panel recommended that drug companies include patients at higher risk of having heart problems, including those who are heavier, older and sicker, in their clinical...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.